DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 089574
NDA 089574 describes A-METHAPRED, which is a drug marketed by Abbott, Hospira, and Hospira Inc, and is included in fourteen NDAs. Additional details are available on the A-METHAPRED profile page.
The generic ingredient in A-METHAPRED is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
The generic ingredient in A-METHAPRED is methylprednisolone sodium succinate. There are forty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the methylprednisolone sodium succinate profile page.
Summary for 089574
| Tradename: | A-METHAPRED |
| Applicant: | Abbott |
| Ingredient: | methylprednisolone sodium succinate |
| Patents: | 0 |
| Therapeutic Class: | Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Inflammatory Bowel Disease Agents |
| Formulation / Manufacturing: | see details |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 125MG BASE/VIAL | ||||
| Approval Date: | Feb 22, 1991 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
